Log in

RegulatoryEconomic Times

US drug regulator classifies Aurobindo Pharma arm's Andhra facility as 'voluntary action indicated'

Neutral0

GreyOak summary

Aurobindo Pharma's subsidiary, Apitoria Pharma, received a Voluntary Action Indicated (VAI) classification from the USFDA for its API manufacturing unit in Andhra Pradesh. The inspection, conducted between August 24-28, 2026, resulted in three observations but no recommended administrative action. The USFDA has officially closed the inspection.

What it affects

Source

Reported by Economic Times

More Aurobindo Pharma news

All Aurobindo Pharma news →

The company today

Price, day change, sector and market cap of the companies this story names
CompanyPriceDay changeSectorMarket cap
Aurobindo PharmaAUROPHARMA · NSE₹1,799.00−0.37%Healthcare₹1.04 lakh crore

Prices as of ; the last session's close when the market is shut. Research, not investment advice.

Latest market news

News Intelligence →

We use cookies

Essential cookies keep GreyOak secure and functional. Optional cookies help improve your experience and platform performance. You can update your preferences anytime.

Cookie Policy